Cargando…
Normal antibody response after COVID-19 during treatment with cladribine
Cladribine is a highly effective, recently available treatment in multiple sclerosis. This case report describes a patient with COVID-19 infection during second year treatment with cladribine. The infection was mild and she was able to mount an adequate immune response with detectable antibodies thr...
Autor principal: | Celius, Elisabeth G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832623/ https://www.ncbi.nlm.nih.gov/pubmed/32882501 http://dx.doi.org/10.1016/j.msard.2020.102476 |
Ejemplares similares
-
Expert-Agreed Practical Recommendations on the Use of Cladribine
por: Meca-Lallana, Virginia, et al.
Publicado: (2022) -
MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine
por: Seferoğlu, Meral, et al.
Publicado: (2021) -
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
por: Mao, Zhifeng, et al.
Publicado: (2018) -
Breastfeeding and treatment of multiple sclerosis
por: Celius, Elisabeth G
Publicado: (2020) -
COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?
por: Gelibter, Stefano, et al.
Publicado: (2021)